Milestone Pharmaceuticals Inc (MIST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $64.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Milestone Pharmaceuticals Inc (MIST) Earnings: Report Dates and Results
Milestone Pharmaceuticals (MIST) is expected to report earnings on Mar 18, 2027. In the quarter ended Sep 30, 2026, Milestone Pharmaceuticals reported EPS of -$0.18, above the -$0.20 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MIST has an expected report date of Mar 18, 2027.
MIST Earnings Call
The latest MIST earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, MIST beat 20, missed 10 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 205.26% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.18 | -$0.20 | -$0.23 - -$0.20 | +10.00% | Beat | N/A | 5 | 0 up, 1 down | Nov 13, 2026 | $2.96M |
| Jun 30, 2026 | -$0.21 | -$0.18 | -$0.22 - -$0.17 | -16.67% | Miss | N/A | 4 | 1 up, 2 down | Aug 12, 2026 | $559000 |
| Mar 31, 2026 | -$0.20 | $0.19 | -$0.18 - $0.57 | -205.26% | Miss | N/A | 4 | 1 up, 0 down | May 13, 2026 | $238000 |
| Dec 31, 2025 | -$0.15 | -$0.16 | -$0.21 - -$0.16 | +6.25% | Beat | N/A | 3 | 2 up, 0 down | Mar 20, 2026 | $1.55M |
| Sep 30, 2025 | -$0.12 | -$0.17 | -$0.20 - -$0.14 | +29.41% | Beat | N/A | 3 | 1 up, 1 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.20 | -$0.18 | -$0.24 - -$0.14 | -11.11% | Miss | N/A | 3 | 1 up, 1 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.31 | -$0.19 | -$0.20 - -$0.19 | -63.16% | Miss | N/A | 2 | 1 up, 1 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$0.19 | -$0.15 | -$0.16 - -$0.14 | -26.67% | Miss | N/A | 2 | 1 up, 0 down | Mar 13, 2025 | $108000 |
| Sep 30, 2024 | -$0.14 | -$0.18 | -$0.19 - -$0.13 | +22.22% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | N/A |
| Jun 30, 2024 | -$0.14 | -$0.20 | -$0.24 - -$0.13 | +30.00% | Beat | N/A | 4 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.21 | -$0.27 | -$0.31 - -$0.21 | +22.22% | Beat | N/A | 4 | 0 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$0.32 | -$0.31 | -$0.35 - -$0.29 | -3.23% | Miss | N/A | 4 | 1 up, 0 down | Mar 21, 2024 | N/A |
| Sep 30, 2023 | -$0.35 | -$0.39 | -$0.41 - -$0.34 | +10.26% | Beat | N/A | 5 | 0 up, 0 down | Nov 13, 2023 | N/A |
| Jun 30, 2023 | -$0.37 | -$0.39 | -$0.41 - -$0.37 | +5.13% | Beat | N/A | 5 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.35 | -$0.39 | -$0.41 - -$0.38 | +10.26% | Beat | N/A | 5 | 0 up, 0 down | May 11, 2023 | $1.00M |
| Dec 31, 2022 | -$0.31 | -$0.33 | -$0.40 - -$0.30 | +6.06% | Beat | N/A | 4 | 0 up, 0 down | Mar 29, 2023 | $3.50M |
| Sep 30, 2022 | -$0.34 | -$0.41 | -$0.45 - -$0.38 | +17.07% | Beat | N/A | 5 | 0 up, 0 down | Nov 10, 2022 | $1.50M |
| Jun 30, 2022 | -$0.39 | -$0.37 | -$0.42 - -$0.34 | -5.41% | Miss | -2050.0% | 5 | 0 up, 0 down | Aug 10, 2022 | N/A |
| Mar 31, 2022 | -$0.33 | -$0.38 | -$0.42 - -$0.32 | +13.16% | Beat | N/A | 5 | 0 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.40 | -$0.36 | -$0.38 - -$0.34 | -11.11% | Miss | N/A | 5 | 0 up, 0 down | Mar 24, 2022 | $15.00M |
| Sep 30, 2021 | -$0.34 | -$0.35 | -$0.52 - -$0.32 | +2.86% | Beat | N/A | 5 | N/A | Nov 12, 2021 | N/A |
| Jun 30, 2021 | $0.02 | -$0.35 | -$0.37 - $0.01 | +105.71% | Beat | N/A | 5 | N/A | Aug 11, 2021 | $15.00M |
| Mar 31, 2021 | -$0.30 | -$0.32 | -$0.40 - -$0.25 | +6.25% | Beat | N/A | 5 | N/A | May 17, 2021 | N/A |
| Dec 31, 2020 | -$0.13 | -$0.41 | -$0.49 - -$0.30 | +68.29% | Beat | N/A | 5 | N/A | Mar 29, 2021 | $57.44M |
| Sep 30, 2020 | -$0.40 | -$0.46 | -$0.57 - -$0.37 | +13.04% | Beat | N/A | 4 | N/A | Nov 13, 2020 | N/A |
| Jun 30, 2020 | -$0.53 | -$0.43 | -$0.56 - -$0.29 | -23.26% | Miss | N/A | 4 | N/A | Aug 12, 2020 | N/A |
| Mar 31, 2020 | -$0.67 | -$0.74 | -$0.80 - -$0.70 | +9.46% | Beat | N/A | 4 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$0.63 | -$0.51 | -$0.60 - -$0.30 | -23.53% | Miss | N/A | 4 | N/A | Mar 6, 2020 | N/A |
| Sep 30, 2019 | -$0.52 | -$0.55 | -$0.58 - -$0.27 | +5.45% | Beat | N/A | 4 | N/A | Nov 13, 2019 | N/A |
| Jun 30, 2019 | -$0.56 | -$0.56 | -$0.70 - -$0.29 | 0.00% | In line | N/A | 4 | N/A | Aug 13, 2019 | N/A |
| Mar 31, 2019 | -$0.41 | -$17.30 | N/A | +97.63% | Beat | N/A | N/A | N/A | May 9, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.78, after -$0.68 the year before. It was -$2.12 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.78 | N/A |
| Dec 31, 2024 | -$0.68 | N/A |
| Dec 31, 2023 | -$1.39 | N/A |
| Dec 31, 2022 | -$1.37 | N/A |
| Dec 31, 2021 | -$1.02 | N/A |
| Dec 31, 2020 | -$1.73 | N/A |
| Dec 31, 2019 | -$2.12 | N/A |
Earnings Calls
The 3 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,300 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,283 | 10 | |
| 2026Q2 | Jun 30, 2026 | 6,785 | 11 | |
| 2026Q1 | Mar 31, 2026 | 7,596 | 11 |
2026Q3 Earnings Call
Opening remarks
Michael Wood Host, LifeSci Advisors Thank you. Good morning, everyone, and welcome to Milestone Pharmaceuticals’ third quarter 2026 financial results and business update conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended September 30, 2026, and recent corporate highlights. The release can be accessed on the Investors Media section of the company’s website, milestonepharma.com. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with Milestone’s business and factors that could cause or contribute to such differences are described in detail in the company’s filings with the SEC, including in the risk factor section of the annual report on Form 10-K for the year ended December 31, 2025, and as updated by subsequent filings, including the quarterly report on Form 10-Q for the quarter ended September 30, 2026. Speaking on today’s call will be Joseph Oliveto, President and Chief Executive Officer, Lorenz Muller, Chief Commercial Officer, and Anthony Krick, Vice President of Finance. I will now turn the call over to Joe to begin. Go ahead.
Joseph Oliveto President and Chief Executive Officer Thank you, Michael, and good morning, everyone. Thank you for joining us today. We are excited to report our third quarter results, and in particular, the continued progress on the launch of CARDAMYST in PSVT. Starting with the KPIs that we report each quarter, we recorded approximately 1,800 prescriptions of CARDAMYST in Q3, representing a 50% increase over the prior quarter, with total scripts from launch through September reaching approximately 3,400. Q3 saw approximately 750 unique healthcare providers prescribe CARDAMYST, a 16% increase over Q2, bringing the total number of unique prescribers to approximately 1,600 from launch through September. As of today, insurance plan formulary coverage of CARDAMYST increased to approximately two-thirds of commercially covered lives, up from approximately 50% that we reported during our second quarter call. Beyond the figures, we remain encouraged by the positive feedback we continue to receive from a growing number of patients about their use of CARDAMYST and what it has meant for them as they deal with the burden of PSVT. We remain confident that steady script growth will improve based on increased awareness and usage of CARDAMYST by healthcare providers and ever-growing positive patient experience. The continued steady increase of payer coverage will result in greater revenue realization over time.
Frequently Asked Questions About MIST
When is Milestone Pharmaceuticals's next earnings date?
Milestone Pharmaceuticals's next earnings report is expected for Mar 18, 2027.
Did MIST beat earnings estimates last quarter?
Yes. Milestone Pharmaceuticals reported EPS of -$0.18 for the quarter ended Sep 30, 2026, above the -$0.20 estimate, a 10.00% surprise.
What EPS do analysts expect from MIST next quarter?
The consensus EPS estimate for Milestone Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.23 from 9 analysts, with estimates from -$0.26 to -$0.21.
How often does MIST beat earnings estimates?
Milestone Pharmaceuticals beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -34.65%.
MIST pages: Overview, Earnings, Forecast, Financials, Competitors